Compare Amgen, Inc. (AMGN) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Sirius XM Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Sirius XM Holdings Inc trades at $30.25 (market cap $10.24B). The key difference: Amgen, Inc. is far larger — about 19.2× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| AMGN | SIRI | |
|---|---|---|
Market Cap | $196.12B | $10.24B |
Sector | Health | Media |
52-Week High | $388.16 | $30.75 |
52-Week Low | $271.18 | $19.92 |
Enterprise Value | $241.41B | $19.91B |
Dividend Yield | 2.77% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SIRI trades at $30.42, down 0.88% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows solid fundamentals with a P/E of 12.89, P/B of 0.87, and consistent earnings beats in recent quarters. Recent developments include upcoming Q2 2026 results on July 30, 2026, and inclusion in the S&P MidCap 400 index.
Outlook remains positive with analyst consensus at Buy (58%) and a $31.17 price target. Key opportunities include strong cash flow and dividend yield, while risks involve competitive pressures and high debt levels. The stock offers value characteristics with upside potential near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
